-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Mavorixafor for Treatment of WHIM Syndrome

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
Hematology Disease Topics & Pathways:
Drug development, Treatment Considerations
Monday, December 9, 2024, 4:30 PM-6:00 PM

Alison R. Moliterno, MD

DNH/OCHEN/CDER, Food and Drug Administration, Silver Spring, MD

Disclosures: No relevant conflicts of interest to declare.

See more of: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>